What drove today’s intraday move in JNJ.DE stock?

JNJ.DE stock moved intraday after a Q4 beat and raised 2026 guidance, offset by legal and tariff headlines. Strong Darzalex and Tremfya sales contrasted with Stelara pressure and tariff uncertainty.

How does valuation look for JNJ.DE stock after the report?

JNJ.DE stock trades at a trailing PE of **20.81** with EPS **€8.91**. The premium reflects strong ROE and cash flow, but the price to book and price to free cash flow are elevated versus some peers.

What price action should investors watch for JNJ.DE stock next?

Watch near-term support at **€178.24**, the 50-day average **€176.80**, and resistance near **€181.49**. Monitor volume spikes and Darzalex sales updates for fresh catalysts.

Does Meyka AI provide a forecast for JNJ.DE stock?

Yes. Meyka AI's forecast model projects a monthly price of **€184.28** and a yearly projection of **€151.18**. These are model outputs and not investment guarantees.

DE Stocks

Q4 beat, stock slips intraday: JNJ.DE Johnson & Johnson XETRA 21 Jan 2026

ByDanny Kontos January 21, 2026

Johnson & Johnson reported a fourth-quarter beat and raised 2026 guidance, yet JNJ.DE stock is trading lower intraday on 21 Jan 2026. The company posted adjusted quarterly EPS above estimates and stronger-than-expected sales in Innovative Medicines. Investors reacted to mixed signals: durable product growth but headline legal and tariff noise. We review the numbers, drivers and what to watch next for the XETRA-listed shares.